Literature DB >> 12506055

Regulation of estrogen receptors and MMP-2 expression by estrogens in human retinal pigment epithelium.

Maria E Marin-Castaño1, Sharon J Elliot, Mylen Potier, Michael Karl, Liliane J Striker, Gary E Striker, Karl G Csaky, Scott W Cousins.   

Abstract

PURPOSE: Age-related macular degeneration (ARMD) is characterized by progressive thickening and accumulation of various lipid-rich extracellular matrix (ECM) deposits under the retinal pigment epithelium (RPE). ECM dysregulation probably contributes to the pathologic course of ARMD. By activating estrogen receptors (ERs), estrogens regulate the expression of genes relevant in the turnover of ECM, among them matrix metalloproteinase (MMP)-2. Estrogen deficiency may predispose to dysregulated synthesis and degradation of ECM, leading to accumulation of collagens and other proteins between the RPE and its basement membrane. The purposes in the current study were to confirm the expression of ERs in human RPE, to elucidate whether these ERs are functional, and to test whether 17beta-estradiol (E(2)) regulates expression of ERs and MMP-2.
METHODS: Expression of ERs was examined in freshly isolated human RPE monolayer and in cultured human RPE cells, by using total RNA for RT-PCR and protein extracts for Western blot analysis. Supernatants were collected from freshly isolated human RPE and from cultured human RPE to assess MMP-2 activity by zymography and protein expression by Western blot. The transcriptional activity of ERs was studied in transfection experiments with an estrogen-responsive reporter construct. All these studies were preformed in the presence or absence of E(2) (10(-11) and 10(-7) M).
RESULTS: Human RPE isolated from female and male individuals expressed both ER subtypes alpha and beta at the mRNA and protein levels. Treatment of cultured RPE cells with 10(-10) M E(2) increased expression of mRNA and protein of both receptor subtypes. E(2) (10(-10) M) also increased MMP-2 activity (approximately 2.2-fold) and protein expression (approximately 2.5-fold). In contrast, there was no change in ER levels and MMP-2 activity at higher E(2) concentrations (10(-8) M), compared with baseline. Preincubation of cells with 10(-7) M pyrrolidinedithiocarbamate (PDTC), an inhibitor of nuclear factor (NF)-kappaB, abolished the increase in MMP-2 activity and protein expression induced by E(2) at 10(-10) M.
CONCLUSIONS: Both ER subtypes are expressed in RPE and regulated in a dose-dependent fashion by E(2). Estrogens similarly regulate MMP-2. This estrogen-induced effect is, at least in part, mediated through NF-kappaB. These data support the hypothesis that estrogens may exert biological function in RPE through ERs and that estrogen deficiency or excess may cause dysregulation of molecules that influence the turnover of ECM in Bruch's membrane associated with ARMD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12506055     DOI: 10.1167/iovs.01-1276

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  31 in total

1.  Embryonic exposure to tetrabromobisphenol A and its metabolites, bisphenol A and tetrabromobisphenol A dimethyl ether disrupts normal zebrafish (Danio rerio) development and matrix metalloproteinase expression.

Authors:  Jessica M McCormick; Michael S Paiva; Max M Häggblom; Keith R Cooper; Lori A White
Journal:  Aquat Toxicol       Date:  2010-07-23       Impact factor: 4.964

Review 2.  Emerging roles for nuclear receptors in the pathogenesis of age-related macular degeneration.

Authors:  Goldis Malek; Eleonora M Lad
Journal:  Cell Mol Life Sci       Date:  2014-08-26       Impact factor: 9.261

3.  Estrogen receptor beta protects against in vivo injury in RPE cells.

Authors:  Sharon J Elliot; Paola Catanuto; Diego G Espinosa-Heidmann; Pedro Fernandez; Eleut Hernandez; Peter Saloupis; Kenneth Korach; Michael Karl; Scott W Cousins
Journal:  Exp Eye Res       Date:  2009-09-30       Impact factor: 3.467

4.  Macular function measured by binocular mfERG and compared with macular structure in healthy children.

Authors:  Anna E C Molnar; Sten O L Andreasson; Eva K B Larsson; Hanna M Åkerblom; Gerd E Holmström
Journal:  Doc Ophthalmol       Date:  2015-10-18       Impact factor: 2.379

5.  Effects of chronic and acute oestrogen replacement therapy in aged animals after experimental stroke.

Authors:  F Liu; S E Benashski; Y Xu; M Siegel; L D McCullough
Journal:  J Neuroendocrinol       Date:  2012-02       Impact factor: 3.627

6.  Research resource: nuclear receptor atlas of human retinal pigment epithelial cells: potential relevance to age-related macular degeneration.

Authors:  Mary A Dwyer; Dmitri Kazmin; Peng Hu; Donald P McDonnell; Goldis Malek
Journal:  Mol Endocrinol       Date:  2011-01-14

7.  Angiotensin II-induced MMP-2 activity and MMP-14 and basigin protein expression are mediated via the angiotensin II receptor type 1-mitogen-activated protein kinase 1 pathway in retinal pigment epithelium: implications for age-related macular degeneration.

Authors:  Marianne Pons; Scott W Cousins; Oscar Alcazar; Gary E Striker; Maria E Marin-Castaño
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

8.  Retinal pigment epithelium protection from oxidant-mediated loss of MMP-2 activation requires both MMP-14 and TIMP-2.

Authors:  Sharon Elliot; Paola Catanuto; William Stetler-Stevenson; Scott W Cousins
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-04       Impact factor: 4.799

9.  Regulation of angiotensin II receptors and extracellular matrix turnover in human retinal pigment epithelium: role of angiotensin II.

Authors:  Gary E Striker; Francoiçe Praddaude; Oscar Alcazar; Scott W Cousins; Maria E Marin-Castaño
Journal:  Am J Physiol Cell Physiol       Date:  2008-10-15       Impact factor: 4.249

10.  17beta-Estradiol inhibits matrix metalloproteinase-2 transcription via MAP kinase in fibroblasts.

Authors:  Shokoufeh Mahmoodzadeh; Elke Dworatzek; Stephan Fritschka; Thi Hang Pham; Vera Regitz-Zagrosek
Journal:  Cardiovasc Res       Date:  2009-10-27       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.